Revenues Tell The Story For BrightGene Bio-Medical Technology Co., Ltd. (SHSE:688166) As Its Stock Soars 25%
Mar 09
Have your own idea? Try our Stock Screener
Chinese (SSE) Pharma Industry Analysis
UpdatedMar 12, 2025
DataAggregated Company Financials
Companies219
- 7D0.9%
- 3M-6.7%
- 1Y-0.9%
- YTD2.0%
Over the last 7 days, the Pharma industry has remained flat, although notably Chengdu Kanghong Pharmaceutical Group gained 16%. In line with that, the industry has also been flat over the past 12 months. Looking forward, earnings are forecast to grow by 17% annually.
Industry Valuation and Performance
Has the Chinese Pharma Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Wed, 12 Mar 2025 | CN¥2.6t | CN¥800.1b | CN¥75.2b | 30.4x | 34x | 3.2x |
| Fri, 07 Feb 2025 | CN¥2.5t | CN¥800.2b | CN¥75.6b | 27.9x | 32.8x | 3.1x |
| Sun, 05 Jan 2025 | CN¥2.5t | CN¥799.8b | CN¥75.6b | 28.2x | 32.8x | 3.1x |
| Tue, 03 Dec 2024 | CN¥2.8t | CN¥799.8b | CN¥75.6b | 32.9x | 36.5x | 3.4x |
| Thu, 31 Oct 2024 | CN¥2.6t | CN¥799.5b | CN¥74.6b | 28.8x | 35.4x | 3.3x |
| Sat, 28 Sep 2024 | CN¥2.5t | CN¥798.6b | CN¥76.3b | 27.9x | 32.7x | 3.1x |
| Mon, 26 Aug 2024 | CN¥2.3t | CN¥804.2b | CN¥78.4b | 24.7x | 29.3x | 2.9x |
| Wed, 24 Jul 2024 | CN¥2.3t | CN¥804.8b | CN¥76.5b | 27.4x | 30.4x | 2.9x |
| Fri, 21 Jun 2024 | CN¥2.4t | CN¥805.5b | CN¥74.6b | 27.2x | 32.6x | 3x |
| Sun, 19 May 2024 | CN¥2.7t | CN¥821.7b | CN¥77.5b | 30.4x | 35.5x | 3.3x |
| Tue, 16 Apr 2024 | CN¥2.6t | CN¥829.0b | CN¥78.5b | 26.8x | 32.6x | 3.1x |
| Thu, 14 Mar 2024 | CN¥2.6t | CN¥832.1b | CN¥80.6b | 27.9x | 32.6x | 3.2x |
| Sat, 10 Feb 2024 | CN¥2.5t | CN¥831.3b | CN¥81.1b | 25x | 30.3x | 3x |
| Mon, 08 Jan 2024 | CN¥2.8t | CN¥830.9b | CN¥79.7b | 30.9x | 34.6x | 3.3x |
| Wed, 06 Dec 2023 | CN¥2.9t | CN¥827.9b | CN¥79.7b | 31.3x | 36x | 3.5x |
| Fri, 03 Nov 2023 | CN¥2.8t | CN¥820.4b | CN¥78.1b | 31.2x | 35.8x | 3.4x |
| Sun, 01 Oct 2023 | CN¥2.8t | CN¥824.9b | CN¥78.6b | 32.3x | 35.8x | 3.4x |
| Tue, 29 Aug 2023 | CN¥2.6t | CN¥820.4b | CN¥78.6b | 29.4x | 33x | 3.2x |
| Thu, 27 Jul 2023 | CN¥2.8t | CN¥810.8b | CN¥76.9b | 33x | 36.5x | 3.5x |
| Sat, 24 Jun 2023 | CN¥2.8t | CN¥809.7b | CN¥76.5b | 31.3x | 36.4x | 3.4x |
| Mon, 22 May 2023 | CN¥3.0t | CN¥809.1b | CN¥76.5b | 33.9x | 39.4x | 3.7x |
| Wed, 19 Apr 2023 | CN¥3.0t | CN¥801.5b | CN¥90.5b | 34.1x | 33.4x | 3.8x |
| Fri, 17 Mar 2023 | CN¥2.9t | CN¥780.1b | CN¥83.7b | 37.7x | 34.7x | 3.7x |
| Sun, 12 Feb 2023 | CN¥2.9t | CN¥774.5b | CN¥83.0b | 36.1x | 35.1x | 3.8x |
| Tue, 10 Jan 2023 | CN¥2.8t | CN¥772.3b | CN¥82.1b | 34.4x | 34.1x | 3.6x |
| Thu, 08 Dec 2022 | CN¥2.9t | CN¥767.8b | CN¥81.9b | 37.7x | 34.9x | 3.7x |
| Sat, 05 Nov 2022 | CN¥2.7t | CN¥767.3b | CN¥82.0b | 34.4x | 33.3x | 3.6x |
| Mon, 03 Oct 2022 | CN¥2.4t | CN¥760.3b | CN¥79.5b | 30.4x | 30.3x | 3.2x |
| Wed, 31 Aug 2022 | CN¥2.6t | CN¥759.2b | CN¥81.2b | 30.8x | 31.5x | 3.4x |
| Fri, 29 Jul 2022 | CN¥2.7t | CN¥744.7b | CN¥81.1b | 31.5x | 33.1x | 3.6x |
| Sun, 26 Jun 2022 | CN¥2.7t | CN¥739.5b | CN¥81.9b | 32.3x | 33.5x | 3.7x |
| Tue, 24 May 2022 | CN¥2.6t | CN¥740.5b | CN¥81.7b | 33.2x | 32.1x | 3.5x |
| Thu, 21 Apr 2022 | CN¥2.6t | CN¥727.4b | CN¥75.9b | 33x | 34.1x | 3.6x |
| Sat, 19 Mar 2022 | CN¥2.9t | CN¥727.2b | CN¥77.7b | 35x | 37x | 4x |
Price to Earnings Ratio
37x
Current Industry PE
- Investors are relatively neutral on the Chinese Pharmaceuticals industry at the moment, indicating that they anticipate long term growth rates to remain steady.
- The industry is trading close to its 3-year average PE ratio of 33.8x.
- The industry is trading close to its 3-year average PS ratio of 3.4x.
Past Earnings Growth
- The earnings for companies in the Pharmaceuticals industry have remained mostly flat over the last three years.
- Meanwhile revenues for these companies have grown 3.2% per year.
- This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased and as a result, profits have held steady.
Industry Trends
Which industries have driven the changes within the Chinese Healthcare industry?
| CN Market | 2.04% | |
| Healthcare | 0.67% | |
| Pharma | 0.86% | |
| Pharma | 0.86% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 002773 Chengdu Kanghong Pharmaceutical Group | CN¥22.30 | 16.1% +CN¥2.8b | 27.6% | PE17.2x | |
| 688166 BrightGene Bio-Medical Technology | CN¥40.75 | 15.3% +CN¥2.3b | 31.5% | PE87.6x | |
| 300723 ApicHope Pharmaceutical Group | CN¥24.20 | 23.8% +CN¥2.1b | -3.0% | PS5.7x | |
| 002653 Haisco Pharmaceutical Group | CN¥34.84 | 5.7% +CN¥2.1b | 35.8% | PE81.2x | |
| 002755 Beijing Aosaikang Pharmaceutical | CN¥16.38 | 13.9% +CN¥1.9b | 72.2% | PE93.2x |
